Roman Willi

1.7k total citations
25 papers, 772 citations indexed

About

Roman Willi is a scholar working on Pathology and Forensic Medicine, Cellular and Molecular Neuroscience and Neurology. According to data from OpenAlex, Roman Willi has authored 25 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 5 papers in Cellular and Molecular Neuroscience and 4 papers in Neurology. Recurrent topics in Roman Willi's work include Multiple Sclerosis Research Studies (8 papers), Peripheral Neuropathies and Disorders (4 papers) and Nerve injury and regeneration (4 papers). Roman Willi is often cited by papers focused on Multiple Sclerosis Research Studies (8 papers), Peripheral Neuropathies and Disorders (4 papers) and Nerve injury and regeneration (4 papers). Roman Willi collaborates with scholars based in Switzerland, Germany and United States. Roman Willi's co-authors include Joram Feldon, Sandra Giovanoli, Urs Meyer, Christine Winter, Martin E. Schwab, Juliet Richetto, Marco Andrea Riva, Mareike Voget, Manfred Schedlowski and Preben Bo Mortensen and has published in prestigious journals such as Science, Journal of Neuroscience and Neurology.

In The Last Decade

Roman Willi

23 papers receiving 763 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roman Willi Switzerland 12 222 175 174 147 138 25 772
Daniel Richter Germany 17 190 0.9× 69 0.4× 184 1.1× 103 0.7× 280 2.0× 26 1.3k
Kayla M. Quinnies United States 9 234 1.1× 39 0.2× 106 0.6× 137 0.9× 45 0.3× 11 868
Tamar L. Ben-Shaanan Israel 9 178 0.8× 36 0.2× 121 0.7× 122 0.8× 61 0.4× 11 1.0k
Moogeh Baharnoori Canada 11 117 0.5× 90 0.5× 78 0.4× 81 0.6× 117 0.8× 28 490
Adi Wilf‐Yarkoni Israel 11 117 0.5× 62 0.4× 97 0.6× 163 1.1× 70 0.5× 24 496
Michal Cardon Israel 9 396 1.8× 78 0.4× 163 0.9× 202 1.4× 34 0.2× 9 1.1k
Andrea Francesca Salvador United States 7 172 0.8× 53 0.3× 111 0.6× 87 0.6× 26 0.2× 8 661
Hilla Azulay‐Debby Israel 9 154 0.7× 42 0.2× 88 0.5× 93 0.6× 50 0.4× 11 874
Maya Schiller Israel 9 196 0.9× 38 0.2× 122 0.7× 122 0.8× 60 0.4× 9 1.2k
Robert M. Schwarcz United States 24 331 1.5× 211 1.2× 450 2.6× 182 1.2× 98 0.7× 50 1.9k

Countries citing papers authored by Roman Willi

Since Specialization
Citations

This map shows the geographic impact of Roman Willi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roman Willi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roman Willi more than expected).

Fields of papers citing papers by Roman Willi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roman Willi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roman Willi. The network helps show where Roman Willi may publish in the future.

Co-authorship network of co-authors of Roman Willi

This figure shows the co-authorship network connecting the top 25 collaborators of Roman Willi. A scholar is included among the top collaborators of Roman Willi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roman Willi. Roman Willi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lefèvre, Gilbert, Xue Tian, Roman Willi, et al.. (2025). Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Participants (P12-1.003). Neurology. 104(7_Supplement_1).
2.
Willi, Roman, et al.. (2024). Implementations for Scattering at 1.8 Volt Between Battery-Less Transponder and Mobile Telephones. IEEE Journal of Radio Frequency Identification. 8. 671–676. 1 indexed citations
3.
Wiendl, Heinz, Laura Airas, Tanuja Chitnis, et al.. (2023). Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 80. 105315–105315. 1 indexed citations
4.
Ziemssen, Tjalf, Douglas L. Arnold, Enrique Álvarez, et al.. (2022). Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology. 13. 852563–852563. 28 indexed citations
5.
Yu, Huixin, Gordon Graham, Olivier J. David, et al.. (2022). Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. CNS Drugs. 36(3). 283–300. 24 indexed citations
6.
Hauser, Stephen L., Anne H. Cross, Kevin Winthrop, et al.. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal. 28(10). 1576–1590. 45 indexed citations
7.
Gärtner, Jutta, Stephen L. Hauser, Amit Bar‐Or, et al.. (2022). Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis Journal. 28(10). 1562–1575. 55 indexed citations
8.
Bar‐Or, Amit, Xavier Montalbán, Harald Kropshofer, et al.. (2022). Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial. Neurology and Therapy. 12(1). 303–317. 10 indexed citations
9.
Wiendl, Heinz, Laura Airas, Tanuja Chitnis, et al.. (2022). Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (P7-4.003). Neurology. 98(18_supplement). 1 indexed citations
10.
Delgado, Silvia, Mitzi Williams, Morten Bagger, et al.. (2021). Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the ASCLEPIOS I/II and APOLITOS studies (4139). Neurology. 96(15_supplement). 2 indexed citations
11.
Hauser, Stephen L., Amit Bar‐Or, Jeffrey A. Cohen, et al.. (2020). B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356). Neurology. 94(15_supplement). 5 indexed citations
12.
Kappos, Ludwig, Amit Bar‐Or, Jeffrey A. Cohen, et al.. (2019). Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096). Neurology. 92(15_supplement). 1 indexed citations
13.
Willi, Roman, et al.. (2016). On Power-Analysis Resistant Hardware Implementations of ECC-Based Cryptosystems. lncs 2162. 665–669. 3 indexed citations
14.
Giovanoli, Sandra, Harald Engler, Andrea Engler, et al.. (2013). Stress in Puberty Unmasks Latent Neuropathological Consequences of Prenatal Immune Activation in Mice. Science. 339(6123). 1095–1099. 375 indexed citations
15.
Willi, Roman, Anja Harmeier, Sandra Giovanoli, & Urs Meyer. (2013). Altered GSK3β signaling in an infection-based mouse model of developmental neuropsychiatric disease. Neuropharmacology. 73. 56–65. 33 indexed citations
16.
Weinmann, Oliver, Bernd Roschitzki, Roman Gonzenbach, et al.. (2013). Infusion of anti-Nogo-A antibodies in adult rats increases growth and synapse related proteins in the absence of behavioral alterations. Experimental Neurology. 250. 52–68. 11 indexed citations
17.
Willi, Roman & Martin E. Schwab. (2013). Nogo and Nogo receptor: Relevance to schizophrenia?. Neurobiology of Disease. 54. 150–157. 41 indexed citations
18.
Willi, Roman, Oliver Weinmann, Christine Winter, et al.. (2010). Constitutive Genetic Deletion of the Growth Regulator Nogo-A Induces Schizophrenia-Related Endophenotypes. Journal of Neuroscience. 30(2). 556–567. 47 indexed citations
19.
Willi, Roman, et al.. (2009). Gruppenvergiftung mit Blei am Arbeitsplatz. DMW - Deutsche Medizinische Wochenschrift. 134(50). 2556–2560. 2 indexed citations
20.
Willi, Roman, et al.. (2008). Behavioral characterization of mice lacking the neurite outgrowth inhibitor Nogo‐A. Genes Brain & Behavior. 8(2). 181–192. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Richter Breakdown of academic impact, for papers by Kayla M. Quinnies Breakdown of academic impact, for papers by Tamar L. Ben-Shaanan Breakdown of academic impact, for papers by Moogeh Baharnoori Breakdown of academic impact, for papers by Adi Wilf‐Yarkoni Breakdown of academic impact, for papers by Michal Cardon Breakdown of academic impact, for papers by Andrea Francesca Salvador Breakdown of academic impact, for papers by Hilla Azulay‐Debby Breakdown of academic impact, for papers by Maya Schiller Breakdown of academic impact, for papers by Robert M. Schwarcz
Rankless by CCL
2026